Skip Navigation

European Heart Journal 2002 23(20):1575-1579; doi:10.1053/euhj.2002.3173
Copyright © 2002 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Erkens, J.A.
Right arrow Articles by Leufkens, H.G.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Erkens, J.A.
Right arrow Articles by Leufkens, H.G.M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Use of fluorquinolones is associated with a reduced risk of coronary heart disease in diabetes mellitus type 2 patients

J.A. Erkensa,b,f1, O.H. Klungela, R.M.C. Heringsa,c, R.P. Stolkb, J.A. Spoelstraa,b, D.E. Grobbeeb and H.G.M. Leufkensa

a Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht, The Netherlands
b Julius Centre for General Practice and Patient Oriented Research, University Medical Centre Utrecht, Utrecht, The Netherlands
c PHARMO Institute, Utrecht, The Netherlands

revised January 4, 2002; accepted January 8, 2002

Abstract

Aims The aim of the present study was to investigate whether use of specific antibiotic drugs decreases the risk of coronary heart disease in diabetes mellitus type 2 patients.

Methods and Results Data were obtained from the PHARMO Record Linkage System comprising pharmacy records and hospitalizations for all 450000 residents of eight Dutch cities. In a nested case-control study among diabetes mellitus type 2 patients, 244 cases with a first hospitalization for coronary heart disease and 686 controls without coronary heart disease matched on age, sex, calendar time, and registration date in PHARMO RLS were selected. Use of antibiotic drugs among cases and controls was determined over 3 years prior to the event. Use of fluorquinolones for more than 14 days compared to no use of fluorquinolones was associated with a lower risk of coronary heart diseases (ORadj=0·30 (95%CI: 0·12–0·75)). No association between tetracycline, macrolide and lincosamide treatment, or other antibiotic drugs (penicillins, cephalosporines, sulphonamides and trimethoprim), and the risk of coronary heart disease was found.

Conclusion Our results suggest that treatment with fluorquinolones in doses commonly prescribed in routine clinical practice is associated with a reduction in the risk of coronary heart diseases among diabetes mellitus type 2 patients. Copyright 2002 The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved.

Key Words: Antibiotic drugs, coronary heart disease, diabetes mellitus type 2, epidemiology

f1 Correspondence: J. A. Erkens, Department of Pharmacoepidemiology & Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), PO Box 80082, 3508 TB Utrecht, The Netherlands.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Arch Intern MedHome page
B. J. Wells, A. G. Mainous III, and L. M. Dickerson
Antibiotics for the Secondary Prevention of Ischemic Heart Disease: A Meta-analysis of Randomized Controlled Trials
Arch Intern Med, October 25, 2004; 164(19): 2156 - 2161.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
F. Delahaye, E. P. McFadden, and G. de Gevigney
The scourge of coronary disease in diabetic patients: will antibiotics sweeten the pill?
Eur. Heart J., October 2, 2002; 23(20): 1557 - 1559.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.